Live feed08:30:00·68dPRReleasevia QuantisnowFortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionByQuantisnow·Wall Street's wire, on your screen.FBIO· Fortress Biotech Inc.Health Care
